DK1278750T3 - Imidazopyrimidinderivater og triazolopyrimidinderivater - Google Patents

Imidazopyrimidinderivater og triazolopyrimidinderivater

Info

Publication number
DK1278750T3
DK1278750T3 DK01936242T DK01936242T DK1278750T3 DK 1278750 T3 DK1278750 T3 DK 1278750T3 DK 01936242 T DK01936242 T DK 01936242T DK 01936242 T DK01936242 T DK 01936242T DK 1278750 T3 DK1278750 T3 DK 1278750T3
Authority
DK
Denmark
Prior art keywords
derivatives
imidazopyrimidine
triazolopyrimidine
triazolopyrimidine derivatives
imidazopyrimidine derivatives
Prior art date
Application number
DK01936242T
Other languages
Danish (da)
English (en)
Inventor
Ming Wang
Timothy B Lowinger
Takeshi Yura
Noriyuki Yamamoto
Arnel B Concepcion
Gyoonhee Han
Makiko Hiraoka
Hiroko Katsumata
Norihiro Kawamura
Toshio Kokubo
Hiroshi Komura
Yingfu Li
Muneto Mogi
Nagahiro Yoshida
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of DK1278750T3 publication Critical patent/DK1278750T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01936242T 2000-04-28 2001-04-17 Imidazopyrimidinderivater og triazolopyrimidinderivater DK1278750T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000128870A JP2001302667A (ja) 2000-04-28 2000-04-28 イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
PCT/EP2001/004357 WO2001083485A1 (en) 2000-04-28 2001-04-17 Imidazopyrimidine derivatives and triazolopyrimidine derivatives

Publications (1)

Publication Number Publication Date
DK1278750T3 true DK1278750T3 (da) 2004-11-22

Family

ID=18638240

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01936242T DK1278750T3 (da) 2000-04-28 2001-04-17 Imidazopyrimidinderivater og triazolopyrimidinderivater

Country Status (38)

Country Link
US (1) US6911443B2 (ja)
EP (1) EP1278750B1 (ja)
JP (2) JP2001302667A (ja)
KR (1) KR20030009456A (ja)
CN (1) CN1263756C (ja)
AR (1) AR033367A1 (ja)
AT (1) ATE272639T1 (ja)
AU (1) AU783043B2 (ja)
BG (1) BG107166A (ja)
BR (1) BR0110404A (ja)
CA (1) CA2407531A1 (ja)
CZ (1) CZ20023551A3 (ja)
DE (1) DE60104671T2 (ja)
DK (1) DK1278750T3 (ja)
DO (1) DOP2001000151A (ja)
EE (1) EE200200606A (ja)
ES (1) ES2225546T3 (ja)
HK (1) HK1058362A1 (ja)
HR (1) HRP20020943A2 (ja)
HU (1) HUP0300846A2 (ja)
IL (1) IL151919A0 (ja)
MA (1) MA25746A1 (ja)
MX (1) MXPA02010579A (ja)
MY (1) MY141578A (ja)
NO (1) NO20025154L (ja)
NZ (2) NZ526221A (ja)
PE (1) PE20011287A1 (ja)
PL (1) PL358106A1 (ja)
PT (1) PT1278750E (ja)
RU (1) RU2306313C2 (ja)
SI (1) SI1278750T1 (ja)
SK (1) SK15332002A3 (ja)
SV (1) SV2001000416A (ja)
TR (1) TR200402300T4 (ja)
TW (1) TWI222974B (ja)
UA (1) UA72615C2 (ja)
WO (1) WO2001083485A1 (ja)
ZA (1) ZA200207676B (ja)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2278016T3 (es) 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
ES2257616T3 (es) 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
US20070129383A1 (en) * 2003-10-17 2007-06-07 Hiroshi Kuramochi Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
PT1718649E (pt) 2004-01-31 2009-08-06 Actimis Pharmaceuticals Inc Derivados de ácido imidazo[1,2-c]pirimidinilacético
JP2008504294A (ja) * 2004-06-25 2008-02-14 アムジエン・インコーポレーテツド サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
KR20070055563A (ko) 2004-08-23 2007-05-30 와이어쓰 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1854793A4 (en) 2005-02-28 2011-01-26 Japan Tobacco Inc NEW AMINOPYRIDEIN COMPOUND WITH SYK-HEMDERING EFFECT
US7442700B2 (en) * 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1948658A1 (en) * 2005-10-13 2008-07-30 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
SI3034075T1 (sl) * 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
EP2123654A4 (en) 2006-12-28 2011-05-11 Taisho Pharmaceutical Co Ltd pyrazolopyrimidine compound
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
MX2010003182A (es) 2007-09-25 2010-06-02 Actimis Pharmaceuticals Inc Alquiltiopirimidinas como antagonistas de crth2.
CL2008002827A1 (es) 2007-09-25 2009-11-27 Actimis Pharmaceuticals Inc Compuestos derivados de 2-s-bencil pirimidina, antagonistas del receptor crth2; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades alergicas mediadas por eosinofilos y basofilos, tales como asma, rinitis alergica, dermatitis atopica, conjuntivitis alergica, sinusitis y psoriasis, entre otras
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
EP3123864A1 (en) 2008-12-08 2017-02-01 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
ES2744541T3 (es) 2008-12-08 2020-02-25 Gilead Connecticut Inc Inhibidores de imidazopirazina Syk
EP2443123B1 (en) 2009-06-15 2017-04-05 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
PE20130188A1 (es) 2009-12-23 2013-02-21 Takeda Pharmaceutical Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
MX350010B (es) 2010-03-11 2017-08-23 Gilead Connecticut Inc Inhibidores syk de imidazopiridinas.
WO2011130146A1 (en) * 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
RU2013154412A (ru) 2011-05-10 2015-06-20 Мерк Шарп И Доум Корп. Аминопиримидины в качестве ингибиторов syc
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
EP2763974B1 (en) 2011-10-05 2016-09-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
AU2012323399A1 (en) * 2011-10-12 2014-05-29 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
DK2799431T3 (en) * 2011-12-28 2018-03-26 Fujifilm Corp Hitherto unknown nicotinamide derivatives or salts thereof
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
EP2863913B1 (en) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
US9416111B2 (en) 2012-06-22 2016-08-16 Merck Sharp & Dohme Corp. Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
WO2013192098A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
EP2934525B1 (en) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9745295B2 (en) 2013-04-26 2017-08-29 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9499534B2 (en) 2013-04-26 2016-11-22 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
US9657023B2 (en) 2013-07-30 2017-05-23 Gilead Connecticut, Inc. Polymorph of Syk inhibitors
US9382256B2 (en) 2013-07-30 2016-07-05 Gilead Connecticut, Inc. Formulation of Syk inhibitors
PT3076976T (pt) 2013-12-04 2020-12-07 Kronos Bio Inc Métodos para tratar cancros
EP3083559B1 (en) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083560B1 (en) 2013-12-20 2021-10-27 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
EP3116506B1 (en) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
LT3119772T (lt) 2014-03-19 2019-08-26 Boehringer Ingelheim International Gmbh Heteroarilo sik inhibitoriai
EP3169366A1 (en) 2014-07-14 2017-05-24 Gilead Sciences, Inc. Combinations for treating cancers
EA033978B1 (ru) 2015-09-11 2019-12-16 Бёрингер Ингельхайм Интернациональ Гмбх Пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств
WO2019040298A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. SYK INHIBITORY POLYMORPHS
RU2020116178A (ru) 2017-10-19 2021-11-19 Байер Энимэл Хельс ГмбХ Применение сопряженных гетероароматических пирролидонов для лечения и профилактики заболеваний у животных
KR20200088397A (ko) 2017-11-14 2020-07-22 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
KR20200088398A (ko) 2017-11-14 2020-07-22 칠드런'즈 메디컬 센터 코포레이션 인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도
WO2019235572A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 固形がんの処置剤および医薬組成物
EP3804722A4 (en) * 2018-06-06 2022-04-13 National University Corporation Hokkaido University TREATMENT AGENT AND PHARMACEUTICAL COMPOSITION AGAINST GLIOMA
WO2019235571A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 血液がんの処置剤および医薬組成物
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
JP7273172B2 (ja) 2018-10-31 2023-05-12 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害活性を有する置換６－アザベンゾイミダゾール化合物
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483987A (en) * 1983-06-20 1984-11-20 G. D. Searle & Co. 8-Substituted 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines and amides
EP1017682A4 (en) * 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
ES2308821T3 (es) 1997-12-15 2008-12-01 Astellas Pharma Inc. Nuevos derivados de pirimidin-5-carboxamida.
US6673564B2 (en) * 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
IL151919A0 (en) 2003-04-10
WO2001083485A1 (en) 2001-11-08
TWI222974B (en) 2004-11-01
SV2001000416A (es) 2001-07-03
MXPA02010579A (es) 2003-05-14
ZA200207676B (en) 2003-09-25
AU783043B2 (en) 2005-09-22
EP1278750A1 (en) 2003-01-29
CZ20023551A3 (cs) 2003-01-15
CN1439009A (zh) 2003-08-27
DE60104671T2 (de) 2005-12-29
MY141578A (en) 2010-05-14
EP1278750B1 (en) 2004-08-04
JP2001302667A (ja) 2001-10-31
NZ526221A (en) 2005-01-28
NO20025154D0 (no) 2002-10-25
DE60104671D1 (de) 2004-09-09
HUP0300846A2 (hu) 2003-08-28
AR033367A1 (es) 2003-12-17
KR20030009456A (ko) 2003-01-29
US6911443B2 (en) 2005-06-28
AU6220401A (en) 2001-11-12
BR0110404A (pt) 2003-02-11
NO20025154L (no) 2002-10-25
CA2407531A1 (en) 2001-10-25
BG107166A (bg) 2003-06-30
NZ522241A (en) 2004-04-30
PT1278750E (pt) 2004-11-30
CN1263756C (zh) 2006-07-12
HRP20020943A2 (en) 2005-02-28
ES2225546T3 (es) 2005-03-16
ATE272639T1 (de) 2004-08-15
UA72615C2 (en) 2005-03-15
TR200402300T4 (tr) 2004-12-21
PE20011287A1 (es) 2002-02-27
DOP2001000151A (es) 2002-05-15
JP2003535067A (ja) 2003-11-25
EE200200606A (et) 2004-04-15
HK1058362A1 (en) 2004-05-14
SK15332002A3 (sk) 2003-06-03
PL358106A1 (en) 2004-08-09
US20040054179A1 (en) 2004-03-18
MA25746A1 (fr) 2003-04-01
SI1278750T1 (en) 2005-02-28
RU2306313C2 (ru) 2007-09-20

Similar Documents

Publication Publication Date Title
DK1278750T3 (da) Imidazopyrimidinderivater og triazolopyrimidinderivater
NO991150D0 (no) Pyrazolopyrimidiner og pyrazolotriaziner
AR028622A1 (es) Derivados de tropano utiles en terapia
IS7283A (is) 3-ß-D-ríbófúranósýlþíasól[4,5-d]pýridímín kirnisleifar og notkun þeirra
DE60026297D1 (de) Pyrrolotriazin kinasehemmer
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
ATE325807T1 (de) Purinderivate
NO20041975D0 (no) Bicyklisk oksopyridin og oksopyrimidinderivater
DE60103537D1 (de) Purinderivate
DE60139930D1 (de) Desinfizieruns- und desodorierungsverfahren
WO2002012546A3 (en) BIO-SENSOR ARRAYS AND RELATED METHODS
DK1322597T3 (da) Fremgangsmåde og intermediære
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
DE50208341D1 (de) Triazolopyrimidine
FI20001715A0 (fi) Rankoihin liittyvät järjestelyt ja menetelmät
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
DE50009171D1 (de) Co 2 - kompressor
NO20032821D0 (no) Sea-trosy og beslektede fremgangsmåter
GB2370001B (en) Educational aid
DK1204566T3 (da) Sammenklappelig varebærer og råemne
NO20031588L (no) Substituerte 3,4-dihydro-pyrimido(1,2-a)pyrimidiner og 3,4- dihydropyrazino(1,2-a)pyrimidiner
FR2815229B1 (fr) Cendrier portable
NO993112A (no) Katamaran og trimaranski
DK1325010T3 (da) Substituerede 3,4-dihydro-pyrimido[1,2-a]pyrimidiner og 3,4-dihydro-pyrazino[1,2-a]pyrimidiner